An ongoing Phase III trial aims to further evaluate the drug's clinical efficacy in reducing seizures and affecting behavior and cognition.

The group has already helped pass bills in Arkansas and Oklahoma, and is supporting bills introduced in Florida, Mississippi, and Tennessee.

Two former FDA veterans are worried that a "firewall" between politics and scientific regulatory decisions has been breached, risking the agency's reputation and leadership.

The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.

NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.

NEW YORK – T-Knife Therapeutics plans to begin a clinical trial this year of its PRAME-targeting armored T cell receptor (TCR) therapy, after the company confirmed on Tuesday that the European ...